Benitec Biopharma reports DSMB recommends continuation of BB-301 Phase 1b/2a study after Cohort 1

Benitec Biopharma Inc.

Sixth and final subject of Cohort 1 safely treated with low dose of BB-301 in April 2025.
Independent DSMB reviewed all six Cohort 1 subjects and recommended continuation of enrollment.
Enrollment of Cohort 2 expected to begin in Q4 2025 following positive DSMB recommendation.
Additional clinical study updates for Cohort 1 subjects planned for Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.